Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Maintaining high dose intensity of cytotoxic treatment has been associated with better outcome but little is known about the role of maintaining...

Descripción completa

Detalles Bibliográficos
Autores principales: Mörth, Charlott, Valachis, Antonios, Sabaa, Amal Abu, Molin, Daniel, Flogegård, Max, Enblad, Gunilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182738/
https://www.ncbi.nlm.nih.gov/pubmed/30091025
http://dx.doi.org/10.1007/s00277-018-3437-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182738/
https://www.ncbi.nlm.nih.gov/pubmed/30091025
http://dx.doi.org/10.1007/s00277-018-3437-z

Ejemplares similares